Back to News & Events

Limited Time Enhanced SBIR/STTR Support

For a limited time, the Center for Biotechnology, as part of the NYS Designated Downstate SBIR/STTR Hub, is able to offer enhanced levels of support for SBIR/STTR proposal development and implementation. With support from Empire State Development, New York State companies are eligible to access services to help them learn about, develop, and execute SBIR/STTR proposals. Support during this limited time period includes:

– Access to short webinars and intensive workshops covering major federal agencies within the SBIR/STTR program
– One-on-one iterative proposal development consulting hours with SBIR experts
– Access to professional grant writing services
– Post award implementation consulting

Full details about the program can be found here: https://centerforbiotechnology.org/resources/programs/

Contact Kate Hutchinson (kate.hutchinson@stonybrook.edu) with questions.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1009 [post_author] => 1 [post_date] => 2014-04-11 06:04:29 [post_date_gmt] => 2014-04-11 06:04:29 [post_content] => New research has found that it is possible to cut down the growth of cancer cells at their earliest stages with a new drug. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham and Zuzana Zachar, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism. In collaboration with Cornerstone Pharmaceuticals, Drs. Bingham, Zachar and colleagues at Stony Brook University are evaluating the basic mechanisms of actions behind this class of agents. The relationship with Cornerstone has its roots within Stony Brook's Center for Biotechnology. Read more here. [post_title] => SBU Researchers Developing Drug to Cut Down Growth of Cancer Cells [post_excerpt] => New research has found that it is possible to cut down the growth of cancer cells at their earliest stages with a new drug. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => sbu-researchers-developing-drug-to-cut-down-growth-of-cancer-cells [to_ping] => [pinged] => [post_modified] => 2014-06-16 06:29:36 [post_modified_gmt] => 2014-06-16 06:29:36 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1009 [menu_order] => 225 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2708 [post_author] => 3 [post_date] => 2017-06-06 09:00:23 [post_date_gmt] => 2017-06-06 09:00:23 [post_content] =>

Innovative phase-0 proof-of-concept center continues advancement of commercially promising biomedical innovations.

The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced the recipients of the fourth round of funded projects under the Hub’s technology development and commercialization initiative. Funding for five projects totaling $400,000 has been awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research at Northwell Health. Over the last two years, more than $2.5M has been awarded to further the development of commercially promising technologies. There are two categories of awards under the LIBH funding initiative – Feasibility and Proof-of-Concept. “Feasibility awards” are funded at up to $50,000 and designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept awards provide up to $100,000 for targeted, milestone driven support for further development, testing, and analysis of existing intellectual property. In this cycle, two feasibility awards have been given to Stony Brook University researchers exploring technologies that include a novel anti-fungal for life threatening blood infections and a new computational method for macrocyclic drug discovery. Proof-of-Concept projects this cycle include a drug-sensitive and drug-resistant TB combination therapy, a novel therapeutic for the treatment of colorectal cancer, and a next-generation medical imaging tool with applications in mammography. “While the Long Island Bioscience Hub is only two‐years in existence, it has already had major impacts including the establishment of four companies.” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Additionally, this round of funding further enhances the LIBH-REACH pipeline that already has resulted in eight patent applications, five options/licenses and more than forty SBIR/STTR applications related to REACH technologies and small business clients.” “I applaud the efforts of the Long Island Bioscience Hub as they continue to draw out the cutting edge biomedical innovations that exist within our research labs and their work with faculty innovators and the local bioscience community to accelerate commercial development.” said Dr. Richard Reeder, Vice President for Research at Stony Brook University. “Stony Brook University is deeply committed to the translation of basic research and the Hub’s successes demonstrate that we need to continue to foster the activities of the Hub.” The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission.

Funded Projects –May 2017 Awards

“A Small Molecule Drug for the Treatment of Systemic Candidiasis” Nicolas Carpino, PhD and Jarrod French, Stony Brook University – Feasibility Award

“BRIKARD, a Program for Macrocyclic Drug Discovery” Evangelos Coutsias, PhD, Stony Brook University – Feasibility Award

“Selenium multi-Well Avalanche Detectors for Medical Imaging Applications” Amirhossein Goldan, PhD, Stony Brook University – Proof of Concept Award

“Developing Novel miR-129 Mimic Based Therapeutics for Colorectal Cancer” Jingfang Ju, PhD, Stony Brook University – Proof of Concept Award

“Azasteroid for Combination anti-TB Therapy” Nicole Sampson, PhD, Stony Brook University – Proof of Concept Award

Download a PDF of the press release here. [post_title] => Long Island Bioscience Hub Announces Latest Funded Projects [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-announces-latest-funded-projects [to_ping] => [pinged] => [post_modified] => 2017-06-05 14:55:40 [post_modified_gmt] => 2017-06-05 14:55:40 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2708 [menu_order] => 143 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3404 [post_author] => 3 [post_date] => 2020-01-02 16:35:15 [post_date_gmt] => 2020-01-02 16:35:15 [post_content] => ASPR/BARDA is issuing a Request for Information (RFI) to assist in understanding the developmental landscape of next generation blood products that could be used to treat mechanical trauma and bleeding associated with acute radiation syndrome and potentially supplement the blood supply in the wake of a mass casualty event such as a nuclear or radiological scenario. BARDA intends to use responses to this RFI for planning potential future acquisitions. BARDA seeks pertinent marketplace data to strengthen BARDA’s understanding of the current and future marketplace as well as enhance its ability to obtain quality services and products economically, and to efficiently and lawfully establish potential vendor source files and listings. BARDA will not award any potential contracts under this notice. This is strictly for market research. Link to the RFI: https://bit.ly/2LSjOEc . [post_title] => BARDA RFI: Next Generation Blood Products [post_excerpt] => ASPR/BARDA is issuing a Request for Information (RFI) to assist in understanding the developmental landscape of next generation blood products. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-rfi-next-generation-blood-products [to_ping] => [pinged] => [post_modified] => 2020-01-31 20:01:41 [post_modified_gmt] => 2020-01-31 20:01:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3404 [menu_order] => 81 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

SBU Researchers Developing Drug to Cut Down Growth of Cancer Cells

More Information

Long Island Bioscience Hub Announces Latest Funded Projects

More Information

BARDA RFI: Next Generation Blood Products

More Information